The CRI Anna-Maria Kellen Clinical Accelerator The CRI Anna-Maria Kellen Clinical Accelerator is a unique nonprofit-academia-industry collaboration model that serves as an “incubator” for multi-center clinical trials testing promising new cancer immunotherapy combinations. As part of the CRI Trials umbrella of clinical programs, the Clinical Accelerator powers integrative, science-driven, collaborative clinical research platforms designed to facilitate and de-risk cancer immunotherapy drug development by leveraging the global CRI Network of immuno-oncology experts and CRI’s philanthropic venture fund. Overview Components Clinical Trials Press Clinical Accelerator Components The CRI Anna-Maria Kellen Clinical Accelerator is a venture philanthropy-backed strategy that supports multi-centered clinical trials testing novel immunotherapy combinations in hard-to-treat cancers, such as those of the pancreas, prostate, and ovary. CRI plays a central role, not only in funding these studies but in convening its network of world experts to propose and vet trial concepts that are scientifically sound and mechanistically based; in assuring that the proposed trials are non-redundant and would not be carried out without CRI support; and in securing the relevant agents from biotech and pharmaceutical companies to be used in combination to provide industry quality data that accelerates the adoption of the studied combination into commercial development. Additionally, emphasis is placed on supporting the in-depth, multi-omic correlative assessment of the precious patient blood and tissue samples secured during the trial so that we learn from every patient to accelerate progress toward effective new immunotherapy combinations. CRI Venture Philanthropy Fund Philanthropic dollars fuel the CRI Venture Fund, which deploys capital to accelerate the creation and execution of innovative immunotherapy clinical trials that aim to improve clinical outcomes for cancer patients. The CRI Venture Fund realizes returns on its invested capital based on the clinical and regulatory development of the therapeutics it financially supports. Milestone payments (returns) are based on predetermined clinical and regulatory triggers. Earned milestone payments are then available to support future clinical studies through the CRI Venture Fund. Global Clinical Research Network The CRI Clinical Accelerator research network includes more than 90 of the world’s leading physician-scientists who have expertise in diverse clinical practices, cancer immunotherapy clinical trials, and immune monitoring. CRI’s leadership position in advancing cancer immunology research for more than 65 years has yielded deep relationships with a global network of scientists, clinicians, and research institutions. Based on their areas of expertise, our researchers are organized into different focus groups, called drug selection committees. These committees propose science-based, biologically driven immunotherapy combinations to be studied in our clinical trials. These proposals are prioritized by the Clinical Accelerator leadership team, financed by our Venture Philanthropy Fund, and made possible through our robust relationships with academia and industry. Immuno-Oncology Landscape Analyses The CRI Immuno-Oncology Landscape analyses present unbiased, scientifically curated, and routinely updated overviews of new investigational I-O agents and cancer immunotherapy clinical trials. These analyses allow the Clinical Accelerator to identify opportunities where the testing of novel immunotherapy combinations can generate the most impact. Thus, CRI is better able to support our global research network in creating rational, non-duplicative clinical trials. The results of our analyses are made available to the public on our website in addition to publication in peer-reviewed scientific journals. VIEW OUR LANDSCAPE Centralized Access to Therapies The CRI Clinical Accelerator team actively monitors the rapidly evolving cancer immunotherapy landscape and works directly with industry and nonprofit organizations to source innovative agents for evaluation in our clinical trials. These strategic partnerships have enabled access to more than 40 different clinical-stage agents to date. Our drug selection committees propose how combinations of these agents should be studied in the clinic by members of our global research network. Such combinations include checkpoint inhibitors, therapeutic vaccines, immunomodulators, oncolytic viruses, and many other promising treatments and technologies with high therapeutic potential. Clinical Accelerator Leadership The Clinical and Scientific Advisory Committee guides the clinical vision, strategy, and studies of the Clinical Accelerator. The management team is composed of highly experienced professionals with relevant experience in immunology, business development, regulatory sponsorship, clinical trial management, and data analysis and reporting. This team works closely with members of the scientific leadership in developing, implementing, and executing CRI-sponsored clinical trials. Partnerships The CRI Clinical Accelerator leverages relationships with nonprofits and companies to fund and deliver multi-center studies that could not be accomplished alone. Through these global partnerships, we advance ambitious clinical and translational research aimed at expanding the benefits of immunotherapy to more patients and, ultimately, curing cancer. Our partners provide key support to the program by contributing strategic direction and managing the logistical operations of our trials. They also provide critical funding and/or access to emerging technologies and therapeutic agents. The CRI Clinical Accelerator is proud to be supported by these outstanding organizations and welcomes new partnerships to de-risk novel combination strategies in immuno-oncology. CRI Investments In 2021, CRI decided to pursue early-stage equity investments in private companies that have direct affiliations with CRI and whose mission aligns with that of CRI. Annually, CRI surveys the CRI Network of scientists regarding near-term, early-stage investment opportunities. Criteria for investment includes companies started by CRI scientists or where they hold senior positions. CRI conducts business, financial, legal, and scientific due diligence on identified opportunities. A key element of the scientific due diligence is leveraging CRI’s Network to assist in evaluating the quality and validity of the technology. CRI Investment Portfolio CompanyCRI ConnectionFocusStageSurge TherapeuticsMichael Goldberg, PhD – FounderIntraoperative immunotherapySeriesACartography BiosciencesAnsuman Satpathy, MD, PhD – FounderImmunotherapy target discoverySeries ACellinfinity BioSidi Chen, PhD – FounderCell therapy platformSeedUndisclosed Company FounderImmunometabolismSeed Clinical Accelerator Trials The CRI Anna-Maria Kellen Clinical Accelerator aims to reduce inefficiencies and duplicative efforts by building multi-site, multi-company platform trials with deep translational and correlative science to advance immunotherapy. Below are clinical trials supported by the Clinical Accelerator as of November 2022. Clinical Trials – Active Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC) (NCT04918186) Helen MacKay, MD, Sunnybrook Health Sciences Centre, CanadaKunle Odunsi, MD, PhD, University of ChicagoAnna Tinker, MD, BCCA, Vancouver Cancer Centre, CanadaDmitriy Zamarin, MD, PhD, Memorial Sloan Kettering Cancer Center Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma (REVOLUTION) (NCT04787991) Robert Vonderheide, MD, DPhil, University of PennsylvaniaGeorge Fisher, MD, PhD, Stanford MedicineAndrew Ko, MD, University of California, San FranciscoMark O’Hara, MD, University of PennsylvaniaEileen O’Reilly, MD, Memorial Sloan Kettering Cancer CenterOsama Rama, MD, Dana Farber Cancer InstituteZev Wainberg, MD, University of California, Los AngelesRobert Wolff, MD, The University of Texas MD Anderson Cancer Center Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients with NSCLC (NCT04093167) Adrian Sacher, MD, Princess Margaret Cancer CentreAndrea Fung, MD, PhD, Kingston Health Sciences CentreCheryl Ho, MD, Vancouver Cancer Centre (Study chair)Garth Nicholas, MD, The Ottawa Hospital Research InstitutePeter Ellis, MD, Juravinski Cancer Centre at Hamilton Health SciencesValsamo (Elsa) Anagnostou, MD, Johns Hopkins University (Study chair) Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (PORTER) (NCT03835533) Charles Drake MD, PhD, Columbia UniversityJulie Graff, MD, Oregon Health & Science UniversityKaren Autio, MD, Memorial Sloan Kettering Cancer CenterKristopher Weintzel, MD, Angeles ClinicLarry Fong, MD, University of California, San FranciscoMatt Galsky, MD, Mount SinaiSumit Subhudhi, MD, PhD, MD Anderson Cancer Center (Study chair) Treatment with Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer (NCT03651271) Alexandra Drakaki, MD, PhD, University of California, Los AngelesApostolia Tsimberidou, MD, PhD, MD Anderson Cancer CenterDanny Khalil, MD, PhD, Memorial Sloan Kettering Cancer CenterDavid Oh, MD, PhD, University of California, San FranciscoPadmanee Sharma, MD, PhD, MD Anderson Cancer Center (Study chair)Saad Khan, MD, Stanford UniversityStephen Hodi, MD, Dana Farber Cancer Institute Clinical Trials – Completed Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects with NSCLC (NCT03164772) Hirva Mamdani, MD, Karmanos Cancer InstituteJhanelle Gray, MD, Moffitt Cancer Center (Study chair)Jiaxin Niu, MD, Banner MD AndersonJonathan Thompson, MD, Medical College of WisconsinJoshua Sabari, MD, NYU Langone Safety and Efficacy of APX005M with Gemcitabine and Nab-Paclitaxel with or without Nivolumab in Patients with Previously Untreated Metastatic Pancreatic Adenocarcinoma (NCT03214250) Andrew Ko, MD, University of California, San FranciscoEileen O’Reilly, MD, Memorial Sloan Kettering Cancer CenterGeorge Ficher, MD, Stanford UniversityMark O’Hara, MD, University of PennsylvaniaOsama Rahma, MD, Dana-Farber Cancer InstituteRobert Vonderheide, MD, DPhil, University of Pennsylvania (Study chair)Robert Wolff, MD, MD Anderson Cancer CenterZev Wainberg, MD, University of California, Los Angeles Results O’Hara M, O’Reilly E, Varadhachary G et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. The Lancet Oncology. 2021.O’Hara M, O’Reilly E, Rosemarie M et al. Abstract CT004. A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients. Clinical Trials. 2019. (Abstract presented at AACR Annual Meeting 2019, March 29, 2019, by Mark O’Hara.) Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer (NCT02431559) Blanca Navarro, MD, University Hospital of Lausanne, Lausanne, SwitzerlandBradley Monk, MD, Arizona OncologyDavid O’Malley, MD, Ohio State UniversityGeorge Coukos, MD, PhD, University Hospital of Lausanne, Lausanne, Switzerland (Study chair)Paul DiSilvestro, MD, Woman and Infants HospitalRoisin O’Cearbhail, MD, Memorial Sloan Kettering Cancer Center Results Orcurto A, et al. Successful Treatment with Rituximab of Sjögren’s Syndrome-Associated Organizing Pneumonia in a Patient Treated with PD-L1 Blockade for Ovarian Cancer. Clinical Oncology: Case Report, Vol: 4 Issue: 3, March 10, 2021.O’Cearbhaill R.E., et al. Abstract presented at the Society of Gynecologic Oncology (SGO) 2020 Annual Meeting on Women’s Cancer Webinar Series: Developmental Therapeutics in Gynecological Cancer Webinar. May 28, 2020.O’Cearbhaill R.E., Wolfer A. et al. A phase 1/2 study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian… Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. (Abstract presented at ESMO 2018 Congress, Poster display session, 20 October 2018, by Roisin O’Cearbhaill.) Phase 2 Study of Durvalumab (MEDI4736) in Patients with Glioblastoma (NCT02336165) David Reardon, MD, Dana-Farber Cancer Institute (Study chair)Gavin Dunn, MD, PhD, Washington University, St LouisHui Gan, MD, Austin Hospital, AustraliaJennifer Clarke, MD, MPH, University of California, San FranciscoJorg Dietrich, MD, Mass General HospitalMichael Lim, MD, Johns HopkinsThomas Kaley, MD, Memorial Sloan Kettering Cancer CenterTim Cloughesy, MD, University of California, Los Angeles Results Reardon DA, Kaley TJ, Dietrich J, et al. Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM). Journal of Clinical Oncology. 2019.Reardon D, Kaley T, Dietrich J, et al. ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) + BEVACIZUMAB (BEV) IN BEV-NAÏVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology. November 2018;20(suppl_6):vi10-vi10.Reardon D, Kaley T, Dietrich J, et al. ATIM-12. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH BEVACIZUMAB (BEV)-REFRACTORY RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology. November 2017;19(suppl_6):vi28-vi28.Casey Allie. Checkpoint Inhibitors Show Promise in Glioblastoma. OncLive.com. Published: Friday, Nov 18, 2016. A Phase 1 Study to Evaluate MEDI4736 in Combination with Tremelimumab (NCT01975831) Antoni Ribas, MD, PhD, University of California, Los Angeles Jedd Wolchok, MD, PhD, Memorial Sloan Kettering Cancer Center (Study chair)Kunle Odunsi, MD, UChicago Medicine Comprehensive Cancer CenterMargaret Callahan, MD, PhD, Memorial Sloan Kettering Cancer Center (Study chair)Mario Sznol, MD, Yale UniversityPatrick Dillon MD, University Virginia HealthPatrick Ott, MD, Dana-Farber Cancer InstituteReva Schneider, MD, Mary Crowley Cancer Center Results Callahan MK, Odunsi K, Sznol M, et al. Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) + tremelimumab (TRE) in patients with advanced solid tumors. Journal of Clinical Oncology. 2018. Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001) (NCT01239134) Henry Koon, MD, University HospitalsDale Shepard, MD, PhD, Cleveland ClinicJedd D. Wolchok, MD, PhD, and Margaret Callahan, MD, PhD, Memorial Sloan Kettering Cancer Center Results Zappasodi R, Sirard C, Li Y, et al. Rational design of anti-GITR-based combination immunotherapy. Nature Medicine. 2019. Rational design of anti-GITR-based combination immunotherapy.Koon HB, Shepard DR, Merghoub T, Schaer DA, Sirard CA, Wolchok JD. First-in-human phase 1 single-dose study of TRX-518, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody in adults with advanced solid tumors. Journal of Clinical Oncology. 2018. Studies Supported by Reagents Studies Supported with Reagents A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients (MEL58) (NCT01585350) Craig L. Slingluff Jr., MD, University of Virginia Health System A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer (NCT02015416) Immune Design, Seattle, WA Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers (NCT00291473) Hiroshi Shiku, MD, and Shinichi Kageyama, MD, Mie University School of Medicine, Mie, Japan A phase I study of concomitant WT1 analog peptide and NY-ESO-1 David O’Malley, MD, The Ohio State University Wexner Medical CenterPaul Sabbatini, MD, Memorial Sloan Kettering Cancer Center A phase I study of vaccination with NY-ESO-1 protein mixed with Poly-ICLC, OK-432 (Picibanil®), and ISA-51 (Montanide®) in patients with advanced cancers expressing NY-ESO-1 Yuichiro Doki, PhD, and Hisashi Wada, MD, PhD, Osaka University, Japan A phase IA/IB study of vaccination with NY-ESO-1 protein, Poly-ICLC, and mogamulizumab in patients with adult T cell leukemia/lymphoma expressing NY-ESO-1 Yuzuru Kanakura, PhD, and Hiroyoshi Nishikawa, MD, PhD, Osaka University, Japan A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence (NCT02334735) Nina Bhardwaj, MD, PhD, Icahn School of Medicine at Mount Sinai Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer (Breast 41) (NCT01532960) Catherine M. Diefenbach, MD, NYU Langone Medical Center A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus Poly-ICLC in stage IB-IIIA breast cancer Patrick M. Dillon, MD, University of Virginia Health System A preclinical mouse vaccination experiment to compare the effectiveness of Poly-ICLC to that of the more common QS-21 Samuel Danishefsky, PhD, Memorial Sloan Kettering Cancer Center Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma (Mel63; CHAMP) (NCT02425306) Craig L. Slingluff Jr., MD, University of Virginia Health System Results Singluff CL, Zarour HM, Tawbi HA, et al. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. 2021. Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies (Mel59) (NCT01846143) Victor H. Engelhard, PhD, and Craig L. Slingluff Jr., MD, University of Virginia Health System Safety Study of Adjuvant Vaccine to Treat Melanoma Patients (NCT01079741) Nina Bhardwaj, MD, PhD, Icahn School of Medicine at Mount Sinai Phase I/II trial of a long peptide vaccine (LPV8) + Toll-like receptor agonists for resected stage IIB-IV Craig L. Slingluff Jr., MD, University of Virginia Health System Role of Toll-like receptor 3 in macrophage-mediated programmed cell removal of tumor cells Irving Weissman, MD, Stanford University School of Medicine Safety and immunogenicity of vaccination with XAGE1b long peptides combined with Poly-ICLC in patients with stage III/IV pulmonary adenocarcinoma Christian Taube, MD, and Maarten L. Zandvliet, PhD, Leiden University Medical Center, The Netherlands A Phase 1/2 Study of In Situ Vaccination with Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers (NCT02643303) Craig Slingluff Jr., MD, University of Virginia Health (Study chair)Danae Hamouda, MD, Toledo UniversityElizabeth Gaughan, MD, University of Virginia HealthIgor Puzanov, MD, Roswell Park Cancer InstituteKeisuke Shirai MD, Dartmouth UniversityMegan Kruse, MD, Cleveland Clinic Michael Lowe, MD, Emory UniversityNina Bhardwaj, MD, PhD, Mount Sinai (Study chair) Results Slingluff CL, Dasilva D, Schwarzenberger P, et al. Phase 1/2 study of in situ vaccination with tremelimumab + intravenous (IV) durvalumab + poly-ICLC in patients with select relapsed, advanced cancers with measurable, biopsy-accessible tumors. Journal of Clinical Oncology. 2018.Slingluff CL, et al. Abstract #P246 presented at SITC 2017 Annual Meeting (November 8-12, 2017). Clinical Accelerator Press The CRI Anna-Maria Kellen Clinical Accelerator team and affiliated scientists publish our new developments and contributions in the field of immunotherapy in prestigious journals, blog posts, and press releases. Press Releases Cancer Immunotherapy Clinical Trials Continue to Grow Globally, Combination Approaches Outpace Monotherapy TrialsCRI Press Release, February 10, 2022Cancer Research Institute and RevImmune Announce Dosing of First Patient in New Phase 2 Study Assessing Therapeutic Benefit of Interleukin-7 in Patients with Cancer and COVID-19CRI Press Release, March 30, 2021Combination Drug Strategies Gain Ground in Global Immuno-Oncology Pipeline of PD-1 and PD-L1 Clinical TrialsCRI Press Release, November 11, 2020An Initative Led by Parker Institute for Cancer Immunotherapy and Cancer Research Institute Discovers Keys That Could Unlock Better Personalized Treatments to Destroy CancerCRI Press Release, October 9, 2020Immunotherapy Drug Development Pipeline Continues Significant Growth In 2020 Despite Global Pandemic ImpactCRI Press Release, September 18, 2020Cancer Research Institute and the Mark Foundation for Cancer Research Launch Research Collaboration to Evaluate Liquid Biopsy for More Accurate and Rapid Assessment of Lung Cancer Patient Response to ImmunotherapyCRI Press Release, July 22, 2020Rapid Growth in Global Development of Cancer Cellular Immunotherapies Highlighted by Latest Report from Cancer Research Institute and GlobalDataCRI Press Release, May 26, 2020 Cancer Research Institute and IQVIA Uncover the Impact of COVID-19 Pandemic on Global Oncology Clinical TrialsCRI Press Release, May 18, 2020Latest Global Immuno-Oncology Landscape Report from the Cancer Research Institute Published in Nature Reviews Drug DiscoveryCRI Press Release, September 27, 2019New Report Charts Dramatic Growth in the Global Clinical Trial Landscape for PD-1/L1 Immune Checkpoint InhibitorsCRI Press Release, November 28, 2018New International Research Collaboration Explores Blood-Based Biomarker Testing to Identify Cancer Patients that Could Potentially Respond to ImmunotherapyCRI Press Release, October 2, 2018Foundation for the National Institutes of Health and Cancer Research Institute Announce New Collaboration in Cancer ImmunotherapyCRI Press Release, July 30, 2018Ludwig Cancer Research and Cancer Research Institute Launch Clinical Trial Combining Virotherapy and Immunotherapy to Treat Advanced Colorectal and Ovarian CancersCRI Press Release, July 11, 2018New Report on the Global Landscape of Cancer Cell Therapy Highlights Robust International Pipeline Marked by Rapid GrowthCRI Press Release, May 25, 2018Cancer Research Institute and Canadian Cancer Trials Group Announce Strategic CollaborationCRI Press Release, January 8, 2018The Cancer Research Institute Announces Publication of Comprehensive Immuno-Oncology Landscape Analysis in Annals of OncologyCRI Press Release, December 7, 2017The Cancer Research Institute and Parker Institute for Cancer Immunotherapy Announce First Patients Treated in Pancreatic Cancer Clinical Trial Combining Immunotherapy and ChemotherapyCRI Press Release, September 20, 2017Immunotherapy Data from CRI Clinical Accelerator to Be Presented at ASCO Annual MeetingCRI Press Release, May 23, 2017Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and the Cancer Research Institute Announce Collaboration to Accelerate Immuno-Oncology ResearchCRI Press Release, March 28, 2017Cancer Research Institute Awards Grant to Develop Powerful Genomic Data Resource for Cancer Immunotherapy ResearchersCRI Press Release, January 31, 2017Ludwig Cancer Research and the Cancer Research Institute Initiate Clinical Trial of a Novel Combination Immunotherapy For Ovarian CancerCRI Press Release, April 6, 2016Cancer Research Institute and Ludwig Cancer Research Partner with Targovax to Test Candidate Virotherapy in Early-Phase Clinical TrialsCRI Press Release, November 18, 2015Ludwig Cancer Research and the Cancer Research Institute Evaluate Immunotherapeutic Strategies for Brain Cancer and Other Types of Solid TumorsCRI Press Release, July 8, 2015Ludwig Cancer Research and Cancer Research Institute Collaborate on Evaluation of VentiRx’s Investigational ImmunotherapyCRI Press Release, September 3, 2014 Publications Landscape of cancer cell therapies: trends and real-world dataNature Reviews Drug Discovery, June 1, 2022Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscapeNature Reviews Drug Discovery, February 10, 2022The clinical pipeline for cancer cell therapiesNature Reviews Drug Discovery, June 4, 2021COVID-19 impact on oncology clinical trials: a 1-year analysisNature Reviews Drug Discovery, May 17, 2021Successful Treatment with Rituximab of Sjögren’s Syndrome-Associated Organizing Pneumonia in a Patient Treated with PD-L1 Blockade for Ovarian CancerClinical Oncology: Case Report, March 10, 2021CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b studyThe Lancet Oncology, January 1, 2021Combinations take centre stage in PD1/PDL1 inhibitor clinical trialsNature Reviews Drug Discovery, November 11, 2020Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen PredictionCell, October 9, 2020Immuno-oncology drug development forges on despite COVID-19Nature Reviews Drug Discovery, September 18, 2020Cancer cell therapies: the clinical trial landscapeNature Reviews Drug Discovery, May 26, 2020Impact of COVID-19 on oncology clinical trialsNature Reviews Drug Discovery, May 18, 2020Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance TaskforceJournal for ImmunoTherapy of Cancer, April 1, 2020Trends in clinical development of PD-1/PD-L1 inhibitorsNature Reviews Drug Discovery, November 4, 2019Immuno-Oncology Drug Development Goes GlobalNature Reviews Drug Discovery, September 27, 2019The global pipeline of cell therapies for cancerNature Reviews Drug Discovery, May 30, 2019Immunotherapy and targeted therapy combinations in metastatic breast cancerThe Lancet Oncology, March 2019The clinical trial landscape for PD1/L1 immune checkpoint inhibitorsNature Reviews Drug Discovery, November 28, 2018Trends in the global immuno-oncology landscapeNature Reviews Drug Discovery, October 19, 2018Design and conduct of early clinical studies of immunotherapy agent combinations: Recommendations from the task force on Methodology for the Development of Innovative Cancer TherapiesAnnals of Oncology, September 10, 2018The global landscape of cancer cell therapyNature Reviews Drug Discovery, May 25, 2018Comprehensive analysis of the clinical immuno-oncology landscapeAnnals of Oncology, January 1, 2018A Blueprint to Advance Colorectal Cancer ImmunotherapiesCancer Immunology Research, November 2017Translating Science into Survival: Report on the Second International Cancer Immunotherapy ConferenceCancer Immunology Research, December 2016De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research InstituteCancer Immunology Research, April 2016Translating Science into Survival: Report on the Inaugural International Cancer Immunotherapy ConferenceCancer Immunology Research, January 2016T cell assays and MIATA: the essential minimum for maximum impactImmunity, July 27, 2012The Cancer vaccine Collaborative: a new model of coordinated discoveryCancer Immunology Research, 2012A methodological framework to enhance the clinical success of cancer immunotherapyNature Biotechnology, October 13, 2011Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyondCancer Immunology Immunotherapy, January 2011 Media Mentions COVID’s impact on cancer therapeutics: clinical trial and treatment disruptionsEuropean Pharmaceutical Review, February 19, 2021How COVID-19 Has Impacted Oncology TrialsHealthcare Tech Outlook, February 11, 2021Oncology Centers Examine the Aftermath of COVID-19 on Clinical TrialsOncLive, June 19, 2020Hospitals Are Bracing For a Spike in Cancer Patients as Covid EbbsBloomberg, June 11, 2020COVID-19 slows sign-ups for clinical cancer trialsBecker’s Hospital Review, May 27, 2020IQVIA & Cancer Research Institute Study Reveals Devastating Impact of COVID-19 on Oncology Clinical TrialsTrial Site News, May 24, 2020More Than 200 International Cancer Trials Suspended Due to COVID-19Medscape, May 22, 2020Changes to Global Oncology Trial Management Due to COVID-19Cancer Network, May 20, 2020Biopharma Update on the Novel Coronavirus: May 18BioSpace, May 18, 2020Can Innate Immune Cells Engage in Anti-Tumor Activity?OBR, May 2020Inovio’s Wild Ride And Real ValueSeekingAlpha, March 25, 2020All chips on immuno-oncology is not a good gambleBioCentury, January 13, 2020Takeda sees cell, gene therapy in its future. Is it too late?BioPharma Dive, November 20, 2019Immuno-oncology Boom Doubles Drugs in Development in 2 YearsCancer Network, October 11, 2019How Technology Is Helping Revolutionize Cancer TreatmentForbes, October 4, 2019Cancer immunotherapy boom showing no sign of slowdownBioPharma Dive, September 27, 2019Enough with the me-too drugs. New treatments should be worthy of the people who invest their lives in clinical trialsSTAT, September 4, 2019Immunotherapy: Combine and ConquerNature Medicine, May 7, 2015Fresh funds in hand, VentriRx joins AstraZeneca, Ludwig and CRI for combo immuno-oncology studyFierce Biotech, September 3, 2014 Blog Articles Defining Resistance to Treatment with Anti-PD-1/PD-L1 ImmunotherapyCRI Blog, April 8, 2020CRI-Sponsored Trial Reveals Promising Potential of Immunotherapy Combination in Metastatic Pancreatic CancerCRI Blog, March 31, 2019Advocating for Innovative Clinical Trial DesignCRI Blog, April 25, 2018Immunotherapy in the Fast Lane: CRI’s Clinical Accelerator Takes OffCRI Blog, January 7, 2014 121 Million Invested 19 Trials Supported 1050+ Patients Treated 65+ Articles Published